Article Text
Editorial
Ivabradine and atrial fibrillation: what should we tell our patients?
Statistics from Altmetric.com
Footnotes
-
Competing interests MRC was the UK Principal Investigator for the SHIFT Study, and submitted evidence to NICE on the drug's clinical and cost-effectiveness on behalf of the manufacturer. He holds no stocks or shares in the company.
-
Provenance and peer review Commissioned; internally peer reviewed.
Linked Articles
- Arrhythmias and sudden death